Victory Capital Management Inc. Has $1.16 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Victory Capital Management Inc. lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 163.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,900 shares of the company's stock after buying an additional 24,767 shares during the period. Victory Capital Management Inc.'s holdings in Denali Therapeutics were worth $1,162,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in DNLI. MONECO Advisors LLC increased its position in Denali Therapeutics by 4.6% during the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company's stock worth $265,000 after buying an additional 400 shares during the last quarter. Assetmark Inc. raised its stake in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after acquiring an additional 580 shares during the period. CWM LLC lifted its holdings in Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after purchasing an additional 654 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock worth $152,000 after purchasing an additional 920 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Denali Therapeutics by 5.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company's stock valued at $613,000 after purchasing an additional 1,372 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DNLI. HC Wainwright reiterated a "buy" rating and issued a $90.00 price target on shares of Denali Therapeutics in a research note on Thursday, November 7th. Jefferies Financial Group increased their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Wedbush reduced their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, August 2nd. Finally, Citigroup lifted their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.90.

Insiders Place Their Bets

In other news, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the transaction, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the company's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. The trade was a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 86,578 shares of company stock valued at $2,474,440. 7.90% of the stock is currently owned by insiders.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $24.68 on Wednesday. Denali Therapeutics Inc. has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The stock has a market capitalization of $3.55 billion, a PE ratio of -8.94 and a beta of 1.40. The business has a fifty day moving average price of $27.76 and a two-hundred day moving average price of $24.38.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the business earned ($0.72) earnings per share. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.69 earnings per share for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.